AT ASH 2025 ORAL PRESENTATION, IMMIX BIOPHARMA REPORTS POSITIVE PHASE 2 NXC-201 RESULTS, ADVANCING TOWARD BLA SUBMISSION AS A POTENTIALLY FIRST- AND BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

Reuters · 1d ago

Please log in to view news